North America Infectious Disease Diagnostics Market Forecast to 2030 - Regional Analysis - By Product, Technology, Application Type, Testing Type, and End User

The North America infectious disease diagnostics market was valued at US$18.68 billion in 2022 and is expected to reach US$28.71 billion by 2030; it is estimated to grow at a CAGR of 5.5% from 2022 to 2030.

Increasing Focus on R&D and Funding in Infectious Disease Diagnostics Drive North America Infectious Disease Diagnostics Market

Research and development (R&D) is an essential component of the business of pharmaceutical and biopharmaceutical companies. R&D enables market players to come up with new products for various therapeutic applications with significant medical and commercial potential. Moreover, leading market players invest in R&D to develop advanced technologies and generate more revenue. In response to the growing cases of infectious diseases and the shortage of laboratory capabilities and molecular testing reagents, some diagnostic testing manufacturers offer fast and easy-to-use devices to facilitate out-of-laboratory testing. The simple test kits detect proteins of pathogens from samples or human antibodies that are produced in response to infection in blood or serum.

Following is a list of a few key funding initiatives undertaken by the manufacturers:

• In March 2022, the Global Fund to Fight AIDS, Malaria, and Tuberculosis acclaimed the decision by Canada to contribute CAD 60 million (US$ 43.99 million) to the Global Fund`s COVID-19 Response Mechanism (C19RM). The funding will help provide life-saving diagnostic tests, treatments, and personal protective equipment (PPE) to low- and middle-income countries.

• In September 2021, the Biden-Harris Administration invested US$ 2.1 billion to enhance infection control and prevention activities across the US public health and healthcare sectors. The Biden-Harris administration, operating through the CDC, invested funds in the US rescue programs to address state, local, and territorial health departments and other partner organizations about infectious diseases in the US.

Thus, rising focus on R&D and funding in infectious disease diagnostics is expected to create lucrative opportunities for the growth of the North America infectious disease diagnostics market.

North America Infectious Disease Diagnostics Market Overview

The infectious diseases diagnostics market growth in the US is primarily driven by the increasing prevalence of infectious diseases, rising geriatric population, and growing number of product launches by key players. Aging is a prominent risk factor for infectious diseases as people above 60 generally have compromised immunity. According to a study published by the Population Reference Bureau in 2020, the population of individuals aged 65 and above was 55 million in the US in 2020, and the number is expected to reach 95 million by 2060. Regulatory agencies in the US are imposing favorable policies for the development of point-of-care (POC) products for the diagnosis and treatment of various indications. For instance, in March 2021, the US Food Drug Administration (FDA) authorized Binx Health IO CT/NG Assay for community-based clinics, urgent care settings, and outpatient healthcare facilities; it is the first POC testing product for diagnosing chlamydial and gonorrheal infections. In May 2022, Becton Dickinson and Company (BD), one of the leading global medical technology companies, announced the launch of its new, fully automated, high-throughput molecular diagnostics platform for infectious diseases for the market in the US. The new BD COR MX instrument was launched as an analytical instrument option for the BD COR platform, with 510(k) clearance from the FDA. The BD CTGCTV2 molecular assay, the first test available on the new system, is a single test that detects the three most prevalent non-viral sexually transmitted infections (STIs)-Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV).

North America Infectious Disease Diagnostics Market Segmentation

The North America infectious disease diagnostics market is segmented based on product, technology, application type, testing type, end user, and country.

Based on product, the North America infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held the largest share in 2022.

By technology, the North America infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The immunodiagnostics segment held the largest share in 2022. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.

By application type, the North America infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held a larger share in 2022.

By testing type, the North America infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held a larger share in 2022. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.

By end user, the North America infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held the largest share in 2022.

Based on country, the North America infectious disease diagnostics market is segmented into the US, Canada, and Mexico. The US dominated the North America infectious disease diagnostics market in 2022.

Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA are some of the leading companies operating in the North America infectious disease diagnostics market.